China Universal Asset Management Co., Ltd. Immuneering Corp Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$7.21 - $10.68 $2,638 - $3,908	366 Added 95.56%	749 $5,000
Q3 2023 Oct 30, 2023	BUY	$7.21 - $10.68 $2,638 - $3,908	366 Added 95.56%	749 $6,000
Q2 2023 May 21, 2024	BUY	$6.49 - $13.36 $162 - $334	25 Added 6.98%	383 $3,000
Q2 2023 Jul 27, 2023	BUY	$6.49 - $13.36 $162 - $334	25 Added 6.98%	383 $4,000
Q1 2023 May 21, 2024	BUY	$3.78 - $10.38 $340 - $934	90 Added 33.58%	358 $3,000
Q1 2023 Apr 27, 2023	BUY	$3.78 - $10.38 $340 - $934	90 Added 33.58%	358 $3,000
Q4 2022 May 21, 2024	BUY	$4.09 - $15.0 $1,096 - $4,020	268 New	268 $1,000
Q4 2022 Jan 31, 2023	BUY	$4.09 - $15.0 $85 - $315	21 Added 8.5%	268 $1,000
Q3 2022 Oct 21, 2022	BUY	$5.0 - $14.32 $1,235 - $3,537	247 New	247 $4,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

4.64M

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

1.07M
Shares

$1.93 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

810K
Shares

$1.46 Million
0.0% of portfolio
Black Rock Inc. New York, NY

533K
Shares

$960,055
0.0% of portfolio
Morgan Stanley New York, NY

449K
Shares

$808,759
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

246K
Shares

$443,286
0.0% of portfolio

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $47.5M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account